Moderna, Merck Fall After Melanoma Data Leak
Moderna and Merck shares plummeted after data on the companies' personalized melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. Michelle Fay Cortez has more on "Bloomberg The Close." (Source: Bloomberg)
On October 22, Moderna's stock plummeted 18% following reports of a potential leak regarding its personalized melanoma vaccine data. The company's shares fell to $202.63 from $202.63. The leak reportedly indicated that Moderna's intismeran autogene, when combined with Merck's Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% compared to Keytruda alone.
This figure was lower than the 49% decline observed in Phase II trials. Trading volume surged to 49.3 million shares, about 148% above the three-month average of 19.9 million shares. While Moderna's stock has risen over sixfold in 2026, the leak has raised doubts among investors about the company's prospects.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
